过去一年中添加的文章，按日期排序
[HTML][HTML] FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells
B Mezquita, M Reyes-Farias, M Pons - Biomedicine & Pharmacotherapy, 2024 - Elsevier
36 天前 - … DCV also inhibits the expression of PDL-1, which is responsible for resistance to
immunotherapy in breast cancer cells. The demonstrated low toxicity in many Hepatitis C …
immunotherapy in breast cancer cells. The demonstrated low toxicity in many Hepatitis C …
A dramatic response to an immune checkpoint inhibitor plus chemotherapy in a patient with metastatic metaplastic carcinoma of the breast: A case report
Y Koi, W Tajiri, J Kawasaki, S Akiyoshi, H Ijichi… - … Cancer, 2024 - Wiley Online Library
37 天前 - … of metastatic metaplastic breast carcinoma responding dra… with primary metaplastic
carcinoma of the breast, which … metaplastic breast cancer to chemoimmunotherapy. Npj. …
carcinoma of the breast, which … metaplastic breast cancer to chemoimmunotherapy. Npj. …
[HTML][HTML] Heterogeneity in the Primary Lesions of invasive micropapillary breast carcinoma.
Y Fu, J Cui, J Zhou, F Li, J He, Z Yang - Current Problems in Cancer: Case …, 2024 - Elsevier
37 天前 - … beneficial outcome from immunotherapy treatment. TMB and DDR pathway were
considered as potential biomarkers for better prediction of tumor immunotherapy efficacy. …
considered as potential biomarkers for better prediction of tumor immunotherapy efficacy. …
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple negative breast cancer patients
M Villanova, SM Tolaney, L Min - Endocrine-Related Cancer, 2024 - erc.bioscientifica.com
38 天前 - … with pathological complete response in patients receiving pembrolizumab for
early triple-negative breast cancer. OncoImmunology 12. (doi:10.1080/2162402X.2023.2275846) …
early triple-negative breast cancer. OncoImmunology 12. (doi:10.1080/2162402X.2023.2275846) …
LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
…, HM Horlings, K Van De Vijver, CA Drukker… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … For triple negative breast cancer (TNBC) the addition of immunotherapy to
chemotherapy … However, chemotherapy plus immunotherapy comes with substantial toxicity …
chemotherapy … However, chemotherapy plus immunotherapy comes with substantial toxicity …
319TiP NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
E Bastien, B Grandal, R Sanchez… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … plus immunotherapy in patients with in HER2 low (IHC 1+, IHC 2+/FISH-) advanced
or metastatic breast cancer. … release of tumor-specific antigens with chemotherapy or ADC. …
or metastatic breast cancer. … release of tumor-specific antigens with chemotherapy or ADC. …
[引用][C] 391P Real-world activity of sacituzumab govitecan for metastatic breast cancer
S Morganti, R Kusmick, ME Hughes… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … 3 (0-9) prior lines for MBC, including chemotherapy (CT)(91%, median of 2 prior
lines), immunotherapy (IO)(53%) and T-DXd (3… CT (97%, median of 3 prior lines), CDK4/6 …
lines), immunotherapy (IO)(53%) and T-DXd (3… CT (97%, median of 3 prior lines), CDK4/6 …
253P Single-cell RNA sequencing reveals tumor heterogeneity and potential mechanisms of response/resistance in breast cancer treated with neoadjuvant therapy
M Carausu, D Gacquer, X Wang, S Majjaj… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … Background: Neoadjuvant therapy (NAT) with … -stage aggressive breast
cancer (BC) subtypes such as triplenegative (… patients treated with CT alone versus CT-immunotherapy. …
cancer (BC) subtypes such as triplenegative (… patients treated with CT alone versus CT-immunotherapy. …
[引用][C] … characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
C Helal, L Djerroudi, T Ramtohul, E Laas… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … response (pCR) following neoadjuvant chemo-immunotherapy (NACi) is associated
with improved patient outcomes in early triple-negative breast cancer (TNBC). In this study, …
with improved patient outcomes in early triple-negative breast cancer (TNBC). In this study, …
237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy
MM Jimenez, O Gluz, G Villacampa… - Annals of …, 2024 - annalsofoncology.org
38 天前 - … There is an urgent need for biomarkers to tailor treatment strategies in early-stage
triple-negative breast cancer (eTNBC). Here, we developed and validated the TNBC-DX …
triple-negative breast cancer (eTNBC). Here, we developed and validated the TNBC-DX …